Colorectal cancer risk mapping through Bayesian networks

Prescription data and demographics: An explainable machine learning exploration of colorectal cancer risk factors based on data from Danish national registries

OBJECTIVES

Despite substantial advancements in both treatment and prevention, colorectal cancer continues to be a leading cause of global morbidity and mortality. This study investigated the potential of using demographics and prescribed drug information to predict risk of colorectal cancer using a machine learning approach.

METHODS

Five different machine learning algorithms, including Logistic Regression, XGBoost, Random Forests, kNN, and Voting Classifier, were initially developed and evaluated for their predictive capabilities across various time horizons (3, 6, 12, and 36 months). To enhance transparency and interpretability, explainable techniques were employed to understand the model's predictions and identify the relative contributions of factors like age, sex, social status, and prescribed medications, promoting trust and clinical insights. While all developed models, including simpler ones such as Logistic Regression, demonstrated comparable performance, the Voting Classifier, as an ensemble model, was selected for further investigation due to its inherent diversity and generalizability. This ensemble model combines predictions from multiple base models, reducing the risk of overfitting and improving the robustness of the final prediction.

RESULTS

The model demonstrated consistent performance across these time horizons, achieving a precision consistently above 0.99, indicating high ability in identifying patients at risk. However, the recall remained relatively low (around 0.6), highlighting the model's limitations in comprehensively identifying all at risk patients, despite its high precision. This suggests additional investigations in future studies to further enhance the performance of the proposed model.

CONCLUSION

Machine learning models can identify individuals at higher risk for developing colorectal cancer, enabling earlier interventions and personalized risk management strategies. However, further studies are needed before implementation in clinical practice.